

## Phase 1 clinical trial of recombinant hyaluronidase ALT-BB4

Alteogen Inc.



OTHERS	Phase 1
Product Type	Biological, enzyme
Indication	To increase the absorption and dispersion of an anesthetic or other drugs, injected by subcutaneous or intramuscular administration
Target	Hyaluronic acid
MoA(Mechanism of Action)	Temporarily cleave polymeric hyaluronic acid (one of major components in human subcutaneous structure), facilitating absorption and dispersion of injected high molecular weight proteins/drugs
Competitiveness	ALT-B4 (drug substance of ALT-BB4 and also its protein code name) is a recombinant hyaluronidase, constructed by replacing a domain of human PH20 with that of hyal-1, another endogenous human hyaluronidase. Compared with human PH20, ALT-B4 exhibits higher specific activity with similar or even lower immunogenic potential. When co-formulated with monoclonal antibody, ALT-B4 demonstrated higher thermal stability upon incubation at stress condition. NOAEL was determined as 2 mg/kg with ALT-B4 by rat and monkey single dose and repeat dose toxicity study.
Development Stage	Clinical trial, Ready for marketing authorization application
Route of Administration	Subcutaneous/intramuscular